Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 12, 2008 - Issue 7
Submit an article Journal homepage
257
Views
30
CrossRef citations to date
0
Altmetric
Reviews

MAPK phosphatases as novel targets for rheumatoid arthritis

Jennifer A Ralph Postdoctoral Research Fellow Monash University Department of Medicine, Centre for Inflammatory Diseases, Monash Medical Centre, 246 Clayton Road, Clayton, Melbourne 3168, Australia
, BSc PhD &
Eric F Morand Associate Professor of Medicine and Deputy Director of Rheumatology Monash University Department of Medicine, Centre for Inflammatory Diseases, Monash Medical Centre, 246 Clayton Road, Clayton, Melbourne 3168, Australia +61 3 9594 3564; +61 3 95946512; [email protected]
, MBBS(Hons) FRACP PhD
Pages 795-808 | Published online: 13 Jun 2008

Bibliography

  • Goodson NJ, Wiles NJ, Lunt M, et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46(8):2010-9
  • Wilder RL, Sternberg EM. Neuroendocrine hormonal factors in rheumatoid arthritis and related conditions. Curr Opin Rheumatol 1990;2(3):436-40
  • Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50(7):2264-72
  • Nuki G, Bresnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46(11):2838-46
  • Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;345(15):1098-104
  • van den Berg WB. Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res 2001;3(1):18-26
  • Emery P, Reginster JY, Appelboom T, et al. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford) 2001;40(6):699-702
  • Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96(1):23-43
  • Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996;313(7053):344-6
  • Ramsey-Goldman R. Missed opportunities in physician management of glucocorticoid-induced osteoporosis? Arthritis Rheum 2002;46(12):3115-20
  • Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003;139(5 Pt 1):359-70
  • Nishida E, Gotoh Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem Sci 1993;18(4):128-31
  • Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Ann Rev Immunol 2002;20:55-72
  • Badger AM, Roshak AK, Cook MN, et al. Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures. Osteoarthritis Cartilage 2000;8(6):434-43
  • Ea HK, Uzan B, Rey C, Liote F. Octacalcium phosphate crystals directly stimulate expression of inducible nitric oxide synthase through p38 and JNK mitogen-activated protein kinases in articular chondrocytes. Arthritis Res Ther 2005;7(5):R915-26
  • Masuko-Hongo K, Berenbaum F, Humbert L, et al. Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage: critical roles of the ERK-1/2 and p38 signaling pathways. Arthritis Rheum 2004;50(9):2829-38
  • Mengshol JA, Vincenti MP, Coon CI, et al. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor κB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum 2000;43(4):801-11
  • Schett G, Tohidast-Akrad M, Smolen JS, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000;43(11):2501-12
  • Pakozdi A, Amin MA, Haas CS, et al. Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res Ther 2006;8(4):R132
  • Santos LL, Lacey D, Yang Y, et al. Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factor. J Rheumatol 2004;31(6):1038-43
  • Han Z, Boyle DL, Aupperle KR, et al. Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 1999;291(1):124-30
  • Beyaert R, Cuenda A, Vanden Berghe W, et al. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J 1996;15(8):1914-23
  • Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372(6508):739-46
  • Krause A, Holtmann H, Eickemeier S, et al. Stress-activated protein kinase/Jun N-terminal kinase is required for interleukin (IL)-1-induced IL-6 and IL-8 gene expression in the human epidermal carcinoma cell line KB. J Biol Chem 1998;273(37):23681-9
  • Korb A, Tohidast-Akrad M, Cetin E, et al. Differential tissue expression and activation of p38 MAPK α, β, γ, and δ isoforms in rheumatoid arthritis. Arthritis Rheum 2006;54(9):2745-56
  • Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997;15(18):2169-77
  • Rousseau S, Houle F, Kotanides H, et al. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem 2000;275(14):10661-72
  • Tanaka K, Oda N, Iwasaka C, et al. Induction of Ets-1 in endothelial cells during reendothelialization after denuding injury. J Cell Physiol 1998;176(2):235-44
  • Jackson JR, Bolognese B, Hillegass L, et al. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 1998;284(2):687-92
  • Westra J, Kuldo JM, van Rijswijk MH, et al. Chemokine production and E-selectin expression in activated endothelial cells are inhibited by p38 MAPK (mitogen activated protein kinase) inhibitor RWJ 67657. Int Immunopharmacol 2005;5(7-8):1259-69
  • Read MA, Whitley MZ, Gupta S, et al. Tumor necrosis factor α-induced E-selectin expression is activated by the nuclear factor-κB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways. J Biol Chem 1997;272(5):2753-61
  • Ohno S, Im HJ, Knudson CB, Knudson W. Hyaluronan oligosaccharides induce matrix metalloproteinase 13 via transcriptional activation of NFκB and p38 MAP kinase in articular chondrocytes. J Biol Chem 2006;281(26):17952-60
  • Pietersma A, Tilly BC, Gaestel M, et al. p38 mitogen activated protein kinase regulates endothelial VCAM-1 expression at the post-transcriptional level. Biochem Biophys Res Commun 1997;230(1):44-8
  • Goebeler M, Kilian K, Gillitzer R, et al. The MKK6/p38 stress kinase cascade is critical for tumor necrosis factor-α-induced expression of monocyte-chemoattractant protein-1 in endothelial cells. Blood 1999;93(3):857-65
  • Badger AM, Griswold DE, Kapadia R, et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000;43(1):175-83
  • Badger AM, Cook MN, Lark MW, et al. SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J Immunol 1998;161(1):467-73
  • Murrell GA, Jang D, Williams RJ. Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 1995;206(1):15-21
  • Jang D, Murrell GA. Nitric oxide in arthritis. Free Radic Biol Med 1998;24(9):1511-9
  • Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. Nat Cell Biol 1999;1(2):94-7
  • Hegen M, Gaestel M, Nickerson-Nutter CL, et al. MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis. J Immunol 2006:177(3):1913-7
  • Crotti TN, Smith MD, Weedon H, et al. Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002;61(12):1047-54
  • Mbalaviele G, Anderson G, Jones A, et al. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. J Pharmacol Exp Ther 2006;317(3):1044-53
  • Park CK, Kim HJ, Kwak HB, et al. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption. Int Immunopharmacol 2007;7(12):1507-16
  • Lee HY, Jeon HS, Song EK, et al. CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis: evidence of NF-κB-dependent, CD40-mediated bone destruction in rheumatoid arthritis. Arthritis Rheum 2006;54(6):1747-58
  • Nishikawa M, Myoui A, Tomita T, et al. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 2003;48(9):2670-81
  • Zwerina J, Hayer S, Redlich K, et al. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 2006;54(2):463-72
  • Hayer S, Steiner G, Gortz B, et al. CD44 is a determinant of inflammatory bone loss. J Exp Med 2005;201(6):903-14
  • Medicherla S, Ma JY, Mangadu R, et al. A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. J Pharmacol Exp Ther 2006;318(1):132-41
  • Mihara K, Almansa C, Smeets RL, et al. A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFα. Br J Pharmacol 2008;154(1):153-64
  • Yamaguchi Y, Fujio K, Shoda H, et al. IL-17B and IL-17C are associated with TNF-α production and contribute to the exacerbation of inflammatory arthritis. J Immunol 2007;179(10):7128-36
  • Martel-Pelletier J, Mineau F, Jovanovic D, et al. Mitogen-activated protein kinase and nuclear factor κB together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes: possible role of transactivating factor mitogen-activated protein kinase-activated proten kinase (MAPKAPK). Arthritis Rheum 1999;42(11):2399-409
  • Geppert TD, Whitehurst CE, Thompson P, Beutler B. Lipopolysaccharide signals activation of tumor necrosis factor biosynthesis through the ras/raf-1/MEK/MAPK pathway. Mol Med 1994;1(1):93-103
  • Westra J, Brouwer E, Bos R, et al. Regulation of cytokine-induced HIF-1α expression in rheumatoid synovial fibroblasts. Ann NY Acad Sci 2007;1108:340-8
  • Thiel MJ, Schaefer CJ, Lesch ME, et al. Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms. Arthritis Rheum 2007;56(10):3347-57
  • Lin LL, Wartmann M, Lin AY, et al. cPLA2 is phosphorylated and activated by MAP kinase. Cell 1993;72(2):269-78
  • Huh YH, Kim SH, Kim SJ, Chun JS. Differentiation status-dependent regulation of cyclooxygenase-2 expression and prostaglandin E2 production by epidermal growth factor via mitogen-activated protein kinase in articular chondrocytes. J Biol Chem 2003;278(11):9691-7
  • Kim SJ, Jeong HJ, Moon PD, et al. The COX-2 inhibitor SC-236 exerts anti-inflammatory effects by suppressing phosphorylation of ERK in a murine model. Life Sci 2007;81(11):863-72
  • Sweeney SE, Firestein GS. Mitogen activated protein kinase inhibitors: where are we now and where are we going? Ann Rheum Dis 2006;65(Suppl 3):83-8
  • Han Z, Boyle DL, Chang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001;108(1):73-81
  • Han Z, Chang L, Yamanishi Y, et al. Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum 2002;46(3):818-23
  • Sundarrajan M, Boyle DL, Chabaud-Riou M, et al. Expression of the MAPK kinases MKK-4 and MKK-7 in rheumatoid arthritis and their role as key regulators of JNK. Arthritis Rheum 2003;48(9):2450-60
  • Hammaker DR, Boyle DL, Chabaud-Riou M, Firestein GS. Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis. J Immunol 2004:172(3):1612-8
  • Bhalla US, Ram PT, Iyengar R. MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science 2002;297(5583):1018-23
  • Keyse SM. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr Opin Cell Biol 2000;12(2):186-92
  • Franklin CC, Kraft AS. Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J Biol Chem 1997;272(27):16917-23
  • Chu Y, Solski PA, Khosravi-Far R, et al. The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem 1996;271(11):6497-501
  • Karlsson M, Mandl M, Keyse SM. Spatio-temporal regulation of mitogen-activated protein kinase (MAPK) signalling by protein phosphatases. Biochem Soc Trans 2006;34(Pt 5):842-5
  • Brondello JM, Brunet A, Pouyssegur J, McKenzie FR. The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J Biol Chem 1997;272(2):1368-76
  • Sanchez-Tillo E, Comalada M, Xaus J, et al. JNK1 Is required for the induction of Mkp1 expression in macrophages during proliferation and lipopolysaccharide-dependent activation. J Biol Chem 2007;282(17):12566-73
  • Lasa M, Abraham SM, Boucheron C, et al. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 2002;22(22):7802-11
  • Toh ML, Yang Y, Leech M, et al. Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1β and glucocorticoids. Arthritis Rheum 2004;50(10):3118-28
  • Schliess F, Heinrich S, Haussinger D. Hyperosmotic induction of the mitogen-activated protein kinase phosphatase MKP-1 in H4IIE rat hepatoma cells. Arch Biochem Biophys 1998;351(1):35-40
  • Marchetti S, Gimond C, Chambard JC, et al. Extracellular signal-regulated kinases phosphorylate mitogen-activated protein kinase phosphatase 3/DUSP6 at serines 159 and 197, two sites critical for its proteasomal degradation. Mol Cell Biol 2005;25(2):854-64
  • Brondello JM, Pouyssegur J, McKenzie FR. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 1999;286(5449):2514-7
  • Stewart AE, Dowd S, Keyse SM, McDonald NQ. Crystal structure of the MAPK phosphatase Pyst1 catalytic domain and implications for regulated activation. Nat Struct Biol 1999;6(2):174-81
  • Maier JV, Brema S, Tuckermann J, et al. Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids. Mol Endocrinol 2007;21(11):2663-71
  • Zhang Y, Blattman JN, Kennedy NJ, et al. Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature 2004;430(7001):793-7
  • Zhao Q, Wang X, Nelin LD, et al. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J Exp Med 2006;203(1):131-40
  • Salojin KV, Owusu IB, Millerchip KA, et al. Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol 2006;176(3):1899-907
  • Hammer M, Mages J, Dietrich H, et al. Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J Exp Med 2006;203(1):15-20
  • Chi H, Barry SP, Roth RJ, et al. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci USA 2006;103(7):2274-9
  • Zhao Q, Shepherd EG, Manson ME, et al. The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38. J Biol Chem 2005;280(9):8101-8
  • Wu JJ, Roth RJ, Anderson EJ, et al. Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet-induced obesity. Cell Metab 2006;4(1):61-73
  • Abraham SM, Lawrence T, Kleiman A, et al. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 2006;203(8):1883-9
  • Jeffrey KL, Brummer T, Rolph MS, et al. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat Immunol 2006;7(3):274-83
  • Sun H, Charles CH, Lau LF, Tonks NK. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 1993;75(3):487-93
  • Dorfman K, Carrasco D, Gruda M, et al. Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene 1996;13(5):925-31
  • Liu Y, Shepherd EG, Nelin LD. MAPK phosphatases – regulating the immune response. Nat Rev Immunol 2007;7(3):202-12
  • Aeberli D, Yang Y, Mansell A, et al. Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Lett 2006;580(3):974-81
  • Roger T, Chanson AL, Knaup-Reymond M, Calandra T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur J Immunol 2005;35(12):3405-13
  • Klinman D. Does activation of the innate immune system contribute to the development of rheumatoid arthritis? Arthritis Rheum 2003;48(3):590-3
  • Radstake TR, Roelofs MF, Jenniskens YM, et al. Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum 2004;50(12):3856-65
  • Huang Q, Ma Y, Adebayo A, Pope RM. Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis. Arthritis Rheum 2007;56(7):2192-201
  • Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, et al. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 2007;56(9):2957-67
  • Hu JH, Chen T, Zhuang ZH, et al. Feedback control of MKP-1 expression by p38. Cell Signal 2007;19(2):393-400
  • Chandrasekharan UM, Yang L, Walters A, et al. Role of CL-100, a dual specificity phosphatase, in thrombin-induced endothelial cell activation. J Biol Chem 2004;279(45):46678-85
  • Kinney CM, Chandrasekharan UM, Mavrakis L, Dicorleto PE. VEGF and thrombin induce MAP kinase phosphatase-1 through distinct signaling pathways: role for MKP-1 in endothelial cell migration. Am J Physiol Cell Physiol 2007;294(1):C241-50
  • Furst R, Schroeder T, Eilken HM, et al. MAPK phosphatase-1 represents a novel anti-inflammatory target of glucocorticoids in the human endothelium. FASEB J 2007;21(1):74-80
  • Kassel O, Sancono A, Kratzschmar J, et al. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 2001;20(24):7108-16
  • Chen P, Li J, Barnes J, et al. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J Immunol 2002;169(11):6408-16
  • Yang YH, Toh ML, Clyne CD, et al. Annexin 1 negatively regulates IL-6 expression via effects on p38 MAPK and MAPK phosphatase-1. J Immunol 2006;177(11):8148-53
  • Noguchi T, Metz R, Chen L, et al. Structure, mapping, and expression of erp, a growth factor-inducible gene encoding a nontransmembrane protein tyrosine phosphatase, and effect of ERP on cell growth. Mol Cell Biol 1993;13(9):5195-205
  • Horsch K, de Wet H, Schuurmans MM, et al. Mkp-1/Dusp1 mediates glucocorticoid inhibition of osteoblast proliferation. Mol Endocrinol 2007;21(12):2929-40
  • Calandra T, Bernhagen J, Metz CN, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995;377(6544):68-71
  • Leech M, Metz C, Hall P, et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 1999;42(8):1601-8
  • Leech M, Metz C, Bucala R, Morand EF. Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum 2000;43(4):827-33
  • Aeberli D, Leech M, Morand EF. Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology (Oxford) 2006;45(8):937-43
  • Leech M, Lacey D, Xue JR, et al. Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis Rheum 2003;48(7):1881-9
  • Yang H, Wu GS. p53 Transactivates the phosphatase MKP1 through both intronic and exonic p53 responsive elements. Cancer Biol Ther 2004;3(12):1277-82
  • Li M, Zhou JY, Ge Y, et al. The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. J Biol Chem 2003;278(42):41059-68
  • Doi M, Cho S, Yujnovsky I, et al. Light-inducible and clock-controlled expression of MAP kinase phosphatase 1 in mouse central pacemaker neurons. J Biol Rhythms 2007;22(2):127-39
  • McEvoy AN, Bresnihan B, FitzGerald O, Murphy EP. Cyclooxygenase 2-derived prostaglandin E2 production by corticotropin-releasing hormone contributes to the activated cAMP response element binding protein content in rheumatoid arthritis synovial tissue. Arthritis Rheum 2004;50(4):1132-45
  • Furukawa T, Sunamura M, Motoi F, et al. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 2003;162(6):1807-15
  • Chattopadhyay S, Machado-Pinilla R, Manguan-Garcia C, et al. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene 2006;25(23):3335-45
  • Wang HY, Cheng Z, Malbon CC. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 2003;191(2):229-37
  • Small GW, Shi YY, Higgins LS, Orlowski RZ. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 2007;67(9):4459-66

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.